{"nctId":"NCT00662818","briefTitle":"Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)","startDateStruct":{"date":"2008-03-17","type":"ACTUAL"},"conditions":["Migraine Disorders","Heart Disease","Cerebrovascular Accident","TIA (Transient Ischemic Attack)","Vascular Diseases","Peripheral Vascular Diseases"],"count":165,"armGroups":[{"label":"Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Telcagepant","Drug: Acetaminophen/Paracetamol","Drug: Placebo to Telcagepant","Drug: Placebo to Acetaminophen/Paracetamol"]},{"label":"Placebo and APAP 1000 mg→Telcagepant 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Telcagepant","Drug: Acetaminophen/Paracetamol","Drug: Placebo to Telcagepant","Drug: Placebo to Acetaminophen/Paracetamol"]}],"interventions":[{"name":"Telcagepant","otherNames":[]},{"name":"Acetaminophen/Paracetamol","otherNames":[]},{"name":"Placebo to Telcagepant","otherNames":[]},{"name":"Placebo to Acetaminophen/Paracetamol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stable coronary artery disease for 3 months or more\n* 18 years of age or older with a history of migraine with or without aura\n* Must use acceptable contraception throughout the study\n\nExclusion Criteria:\n\n* Pregnant, breast-feeding, or planning to become pregnant during this study\n* 50 years of age or older when migraines began\n* Other pain syndromes that might interfere with study assessments, uncontrolled psychiatric conditions, dementia, or significant neurological disorders (other than migraine)\n* History of gastric, or small intestinal surgery, or has a disease that causes malabsorption","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Pain Freedom at 2 Hours Post-dose (Period 1, Migraine Attack 1)","description":"Pain Freedom (PF) at 2 hours post-dose (Period 1, Attack 1) defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at baseline to no pain (Grade 0). Headache severity was subjectively rated by the participant at predefined time points on a scale of Grade 0 to Grade 3: Grade 0 - No pain; Grade 1 - Mild pain; Grade 2 - Moderate Pain; and Grade 3 - Severe Pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pain Relief at 2 Hours Post-dose (Period 1, Migraine Attack 1)","description":"Pain Relief (PR) at 2 hours post-dose (first migraine attack), with pain relief defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 at 2 hours post-dose. Headache severity was subjectively rated by the participant at predefined time points on a scale of Grade 0 to Grade 3: Grade 0 - No pain; Grade 1 - Mild pain; Grade 2 - Moderate Pain; and Grade 3 - Severe Pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced an Adverse Event (AE) Within 14 Days Post-dose","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Drug Due to an AE Within 48 Hours Post-dose","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Confirmed Vascular Event Within 48 Hours Post-dose","description":"Confirmed Vascular Event included cardiac events, cerebrovascular events, and peripheral vascular events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Absence of Phonophobia at 2 Hours Post-dose (Period 1, Migraine Attack 1)","description":"The participant recorded whether phonophobia (sensitivity to sound) was present or absent at each of the predefined time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null},{"groupId":"OG001","value":"58.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Absence of Photophobia at 2 Hours Post-dose (Period 1, Migraine Attack 1)","description":"The participant recorded whether photophobia (sensitivity to light) was present or absent at each of the predefined time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"58.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Absence of Nausea at 2 Hours Post-dose (Period 1, Migraine Attack 1)","description":"The participant recorded whether nausea was present or absent at each of the predefined time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"69.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Pain Freedom (SPF) at 2 to 24 Hours Post-dose","description":"SPF from 2 to 24 hours post-dose is defined as PF at 2 hours, with no administration of either rescue medication or the optional second dose and with no occurrence thereafter of a mild/moderate/severe headache during the 2 to 24 hours after dosing with the study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":98},"commonTop":[]}}}